US 11,926,648 B2
Neutralising antibody against dengue for use in a method of prevention and/or treatment of Zika infection
Felix Rey, Paris (FR); Giovanna Barba Spaeth, Paris (FR); Marie-Christine Vaney, Paris (FR); Alexander Rouvinski, Jerusalem (IL); Gavin Screaton, London (GB); and Juthathip Mongkolsapaya, London (GB)
Assigned to INSTITUT PASTEUR, Paris (FR); and IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB)
Filed by IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB); and INSTITUT PASTEUR, Paris (FR)
Filed on Apr. 27, 2021, as Appl. No. 17/241,884.
Application 17/241,884 is a continuation of application No. 16/308,745, granted, now 11,111,274, previously published as PCT/GB2017/051692, filed on Jun. 9, 2017.
Claims priority of application No. 1610162 (GB), filed on Jun. 10, 2016.
Prior Publication US 2021/0355167 A1, Nov. 18, 2021
Int. Cl. C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C07K 14/18 (2006.01); C07K 14/705 (2006.01); G01N 33/569 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61P 31/14 (2018.01); C07K 14/1825 (2013.01); C07K 16/1081 (2013.01); G01N 33/56983 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24171 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
 
1. A composition comprising an isolated neutralizing antibody or antigen binding fragment thereof directed against a flavivirus envelope dimer epitope (EDE) and an adjuvant,
wherein the antibody or fragment comprises six CDRs wherein each CDR comprises an amino acid sequence selected from the group consisting of:
SEQ ID Nos: 15 to 26 and sequences with no more than 30% modification from any one of said SEQ ID No. 15 to 26,
wherein:
(a) said antibody or fragment thereof binds the five polypeptide segments of the dengue virus glycoprotein E ectodomain (sE) consisting of the residues 67-74, residues 97-106, residues 307-314, residues 148-159 and residues 243-251, or corresponding residues of the flavivirus or Zika virus glycoprotein E ectodomain, or consisting of Zika PF13 residues 67-77, residues 97-106, residues 313-315, residues 243-253, residue K373 or corresponding residues of the flavivirus glycoprotein E ectodomain, or
(b) binding is unaffected by presence or absence of dengue N153 (Zika N154) glycan or corresponding residue.